Literature DB >> 35845197

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis.

Azka Tasleem1, Janet Roepke2, Salahuddin Siddiqui3.   

Abstract

Entities:  

Year:  2021        PMID: 35845197      PMCID: PMC9176150          DOI: 10.1002/jha2.299

Source DB:  PubMed          Journal:  EJHaem        ISSN: 2688-6146


× No keyword cloud information.
A 72‐year‐old female presented for evaluation for almost a 5‐year history of gradually worsening anemia with hemoglobin ranging from 8 to 9 g/dl (reference range:12–15 g/dl) and thrombocytosis with platelet count ranging from 500 to 600 × 109/L (reference range: 150–450 × 109/L). Her white blood cell count and differential were in normal range. Laboratory evaluation revealed normal iron, vitamin B12, folate, copper, lactate dehydrogenase, haptoglobin, and reticulocyte count. Serum erythropoietin level was 55.5 mIU/ml (reference range: 2.6–18.5 mIU/ml). Complete metabolic profile was unremarkable. Physical examination showed no palpable splenomegaly. Peripheral blood film showed macrocytic anemia with anisopoikilocytosis, basophilic stippling, rare Pappenheimer bodies, and rare circulating nucleated RBCs. She underwent bone marrow biopsy with cytogenetics and next‐generation sequencing (NGS) for common myeloid mutations. Bone marrow biopsy (Figure 1) showed hypercellular marrow, megakaryocytic hyperplasia with some giant hyperlobated megakaryocytes, erythroid hyperplasia with dyserythropoiesis, and increased reticuloendothelial iron stores with >15% numerous ring sideroblasts. Myeloblasts were <1%. Cytogenetics and fluorescence in situ hybridization (FISH) testing for common myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) panel were normal. Patient tested negative for BCR‐ABL1, CALR and MPL mutation and NGS showed JAK‐2 and SF3B1 mutation.
FIGURE 1

(A–D) Bone marrow biopsy (Figure 1). Hematoxylin and Eosin‐stained marrow clot section showing hypercellular marrow, trilineage hyperplasia (inset A, 20×). Bone marrow aspirate smear, stained with Wright stain showing megakaryocytic hyperplasia with an abnormal hyperlobated/hypersegmented megakaryocyte (inset B, 20×). Hematoxylin and Eosin‐stained biopsy section showing nucleated red cell precursor with irregular nuclear contours (inset C, 100× oil). Iron‐stained aspirate smear, arrow immediately below one of the ringed sideroblasts (inset D, 100× oil)

(A–D) Bone marrow biopsy (Figure 1). Hematoxylin and Eosin‐stained marrow clot section showing hypercellular marrow, trilineage hyperplasia (inset A, 20×). Bone marrow aspirate smear, stained with Wright stain showing megakaryocytic hyperplasia with an abnormal hyperlobated/hypersegmented megakaryocyte (inset B, 20×). Hematoxylin and Eosin‐stained biopsy section showing nucleated red cell precursor with irregular nuclear contours (inset C, 100× oil). Iron‐stained aspirate smear, arrow immediately below one of the ringed sideroblasts (inset D, 100× oil) The presence of platelet count >450 × 109/L, anemia, hypercellular marrow, dyserythropoiesis, and numerous ring sideroblasts led to diagnosis of myelodsyplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis as per 2016 WHO Classification [1]. With thrombocytosis, aspirin can reduce the risk of thrombosis and vasomotor symptoms [2]. In patients with prior history of arterial/venous thrombosis and age >60, the risk of thrombosis is higher [3]; hence, cytoreductive therapy with hydroxyurea can also be considered in addition to aspirin. Anemia is treated using erythropoiesis stimulating agents and transfusion support. If patient has associated anemia and is hydroxyurea‐intolerant, then agents such as lenalidomide, anagrelide, and interferon alpha are used to prevent worsening of anemia [4]. Since our patient had both thrombocytosis and anemia, she was started on anagrelide for cytoreduction, which has a lower risk of causing anemia.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Azka Tasleem and Salahuddin Siddiqui wrote the initial draft of the manuscript. Janet Roepke contributed to pathologic interpretations. The final version of the manuscript was approved by all authors.
  4 in total

1.  Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.

Authors:  Alberto Alvarez-Larrán; Francisco Cervantes; Arturo Pereira; Eduardo Arellano-Rodrigo; Virginia Pérez-Andreu; Juan-Carlos Hernández-Boluda; Ramón Ayats; Carlos Salvador; Ana Muntañola; Beatriz Bellosillo; Vicente Vicente; Luis Hernández-Nieto; Carmen Burgaleta; Blanca Xicoy; Carlos Besses
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

2.  Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

Authors:  Maura Nicolosi; Mythri Mudireddy; Rangit Vallapureddy; Naseema Gangat; Ayalew Tefferi; Mrinal M Patnaik
Journal:  Am J Hematol       Date:  2017-11-10       Impact factor: 10.047

Review 3.  Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Authors:  Ayalew Tefferi; Tiziano Barbui
Journal:  Am J Hematol       Date:  2015-02       Impact factor: 10.047

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.